VivoSeq
Oncology

Rectal Carcinoma

16

Pipeline Programs↗

1

Active Trials↗

11

Companies Involved↗

Rectal Carcinoma is an emerging landscape with 16 programs across 11 companies. The most active players are Meitheal, Shanghai Pharmaceuticals Holding Co., Ltd, Teva. 2 therapies are approved with 5 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

43/100

Pipeline Velocity

0/100

Mech. Concentration

29/100

Completion Rate

78/100

Attrition Rate

18/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

M

Meitheal

1 program

Phase 1S

Shanghai Pharmaceuticals Holding Co., Ltd

1 program

Phase 2Teva logo

Teva

1 program

Phase 2Pfizer logo

Pfizer

1 program

Phase 2BeiGene logo

BeiGene

1 program

Phase 2Taiho Oncology, Inc. logo

Taiho Oncology, Inc.

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

82%

Small molecule

14 of 17 classified programs — the dominant modality here.

18%ALL OTHERSMonoclonal antibody212%Peptide16%

Small molecule leads; the ring shows all 17 classified programs, each share of the total. Modality classified for 100% of 17 pipeline programs.

Analysis

Trial Status

11

clinical trials

Completed7 · 64%
Terminated2 · 18%
Unknown status1 · 9%
Recruiting1 · 9%

Clinical Trials

Trial Activity

11 trials

Study Evaluating the Tailored Management of Locally-advanced Rectal Carcinoma
Recruiting·IInstitut du Cancer de Montpellier - Val d'Aurelle·Phase 2/3·NCT04749108·1,075 enrolled
Study of Therapeutic Targets Tailored Ch and IMRT as Neoadjuvant Treatment in Rectal Carcinoma Patients
Completed·GGrupo Hospital de Madrid·N/A·NCT01366118·16 enrolled
Phase II Study of Up-front Chemotherapy and Neo-adjuvant Short-course Radiotherapy for Resectable Rectal Carcinoma (COLORE)
Completed·IIstituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS·Phase 2·NCT02000050·52 enrolled
Genotype-directed Neoadjuvant Chemoradiation for Rectal Carcinoma
Completed·WWashington University School of Medicine·Phase 2·NCT00682786·135 enrolled
Neoadjuvant Treatment for Advanced Rectal Carcinoma
Completed·UUNICANCER·Phase 3·NCT02551237·103 enrolled
Preoperative Combined Radiochemotherapy for Patients With Rectal Carcinoma
Completed·AAustrian Breast & Colorectal Cancer Study Group·Phase 2·NCT00297141·60 enrolled
A Phase I Study of Oral Topotecan as a Radiosensitizing Agent in Patients With Rectal Carcinoma
Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT00215956·31 enrolled
Multicenter Phase 2 Trial: a Tailored Strategy for Locally Advanced Rectal Carcinoma
Completed·IInstitut du Cancer de Montpellier - Val d'Aurelle·Phase 2·NCT01333709·150 enrolled
Neo-Adjuvant FOLFOX for Rectal Carcinoma
Terminated·—·Phase 2·NCT00832299·2 enrolled
Randomized Study on Neoadjuvant Radio-Chemotherapy in Rectal Carcinoma Dukes B and C
Terminated·AAustrian Breast & Colorectal Cancer Study Group·Phase 3·NCT00309517·700 enrolled
Preoperative S-1/OHP With Radiation Therapy for Low-lying Rectal Carcinoma in Neo-adjuvant Setting
Unknown status·JJapan Clinical Cancer Research Organization·Phase 1/2·NCT01227239·45 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)